- 1 SARS-CoV-2 viral replication persists in the human lung for several weeks after symptom onset
- 2 in mechanically ventilated patients with severe COVID-19: a prospective tissue-sampling study
- 3 Tomasicchio M<sup>1,2</sup>, Jaumdally S<sup>1,2</sup>, Pooran A<sup>1,2</sup>, Esmail A<sup>1,2</sup>, Wilson L<sup>1,2</sup>, Kotze A<sup>1,2</sup>, Semple L<sup>1,2</sup>,
- 4 Meier S<sup>1,2</sup>, Pillay K<sup>5</sup>, Roberts R<sup>5</sup>, Kriel R<sup>5</sup>, Meldau R<sup>1,2</sup>, Oelofse S<sup>1,2</sup>, Mandviwala C<sup>1,2</sup>, Burns J<sup>1,2</sup>,
- 5 Londt R<sup>1,2</sup>, Davids M<sup>1,2</sup>, van der Merwe<sup>1,2</sup> C, Roomaney A<sup>1,2</sup>, Kühn L<sup>1,2</sup>, Perumal T<sup>1,2</sup>, Scott A.J<sup>1,2</sup>,
- 6 Hale M.J<sup>6</sup>, Baillie V<sup>7</sup>, Mahtab S<sup>7</sup>, Williamson C<sup>8</sup>, Joseph R<sup>8</sup>, Sigal A<sup>9</sup>, Joubert I<sup>10</sup>. Piercy J<sup>10</sup>.
- 7 Thomson D<sup>10</sup>, Fredericks DL<sup>10</sup>, Miller MGA<sup>10</sup>, Nunes M.C<sup>7</sup>, Madhi S.A<sup>7</sup>, Dheda K<sup>1,2,3,4</sup>,

#### **Affiliations:**

8

9

- 10 <sup>1</sup> Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine,
- 11 University of Cape Town and UCT Lung Institute, FCape Town, South Africa.
- <sup>2</sup> South African MRC Centre for the Study of Antimicrobial Resistance, University of Cape Town,
- 13 Cape Town, South Africa.
- <sup>3</sup> Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town,
- 15 South Africa.
- <sup>4</sup> Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London
- 17 School of Hygiene & Tropical Medicine, London, UK.
- <sup>5</sup> Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape Town,
- 19 South Africa
- <sup>6</sup> Division of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand.
- <sup>7</sup> South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research
- 22 Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;
- 23 Department of Science and Technology/National Research Foundation South African Research Chair
- 24 Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the
- 25 Witwatersrand, Johannesburg, South Africa.
- <sup>8</sup> Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of
- 27 Cape Town, Cape Town, South Africa.
- 28 <sup>9</sup> Africa Health Research Institute, Durban, South Africa.
- 29 livision of Critical Care, Department of Anaesthesia and Perioperative Medicine, University of
- 30 Cape Town, South Africa.

- 32 Correspondence: Keertan Dheda, Centre for Lung Infection and Immunity, Division of Pulmonology
- and UCT Lung Institute, Dept of Medicine, University of Cape Town, South Africa. E-mail:
- 34 keertan.dheda@uct.ac.za

**Summary** 

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

Background. The immunopathogenesis of severe COVID-19 is incompletely understood. Remdesivir is not recommended in mechanically ventilated (MV) patients. In the upper respiratory tract (URT) replicating (culturable) SARS-CoV-2 is recoverable for ~ 4 to 8 days after symptom onset, however, there is paucity of data about the frequency or duration of replicating virus in the lower respiratory tract (i.e. the human lung). **Methods.** We undertook lung tissue sampling (needle biopsy), shortly after death, in 42 mechanically ventilated (MV) decedents during the Beta and Delta waves. An independent group of 18 ambulatory patents served as a comparative control. Lung biopsy cores from decedents underwent viral culture, histopathological analysis, electron microscopy, transcriptomic profiling, immunohistochemistry and cell-based flow cytometry of deconstructed tissue. Findings. 38% (16/42) of MV decedents had culturable virus in the lung for a median of 15 days (persisting for up to 4 weeks) after symptom onset compared to < ~5 days in the URT of ambulatory patients. Lung viral culture positivity was not associated with comorbidities or steroid use. Delta but not Beta variant lung culture positivity was associated with accelerated death and secondary bacterial infection (p<0.05). NP culture was negative in 23.1% (6/26) of decedents despite lung culture positivity. This, hitherto, undescribed bio-phenotype of lung-specific persisting viral replication was associated with an enhanced transcriptomic pulmonary pro-inflammatory response but concurrent with viral culture positivity. Interpretation. In a sizable subset of patients with acute COVID-19, concurrent, rather than sequential active viral replication continues to drive a heightened pro-inflammatory response in the human lung beyond the second week of illness (despite lack of viral replication in the URT) and was associated with variant-specific increased mortality and morbidity. These findings have potential implications for the design of interventional strategies and clinical management of patients with

Funding. South African Medical Research Council.

severe COVID-19 disease.

### **Evidence before this study**

Previous investigations to understand SARS-CoV-2 viral shedding (determined by PCR or antigen testing) have extensively focused on samples from the upper respiratory tract. The widely accepted view is that acute severe SARS-CoV-2 infection is characterised by a viral replicative phase in the first week of symptomatic illness followed by a pro-inflammatory immunopathologic phase peaking in the second and third weeks of illness. However, it remains unclear whether detection of SARS-CoV-2 beyond 2 weeks after symptom onset in published studies represent active replication competent virus because it may represent residual genomic or antigenic material in the tissue. Indeed, active replicating virus using serial culture has been shown to only persist for up to approximately one week after symptom onset in the upper respiratory tract. We could not find any published studies that comprehensively interrogated the upper and lower respiratory tract for culturable virus and mapped out their related clinical determinants and host immunological status. We hypothesised that there is compartment-specific uncoupling of viral replication in acute severe COVID-19 i.e. replicating virus, can persist in the lower respiratory tract beyond 10 days from symptoms onset, independent of its persistence in the upper respiratory tract, and this persistence may be associated with altered pulmonary immunity, and would have implications for antiviral and immunomodulatory therapy.

# Added value of this study

We have identified a, hitherto, undescribed bio-phenotype of acute severe COVID-19 characterised by persisting viral replication in the lung for up to 4 weeks after symptom onset. This phenotype was associated with variant-specific accelerated death and a higher rate of secondary bacterial infection. We further found that this phenotype of replicating viral persistence was also associated with an exaggerated inflammatory response and attenuated T-cell immunity in the lung (based on histopathological and transcriptomic studies). This challenges the traditional view that viral replication occurs during the first 5 to 10 days of illness, which is followed by an effector or hyperinflammatory phase. This is the first study, to our knowledge, to systematically culture virus from the human lung and map out its related clinical determinants, and which describes the human

91 lung transcriptomic profile of culture-positive versus culture-negative patients with severe COVID-19 92 disease. 93 Implications of all the available evidence 94 The Infectious Disease Society of America (and many other global guidelines) currently recommend 95 the use of antivirals like remdesivir for only 5 days in hospitalised patients, and do not recommend the 96 use of antiviral agents in mechanically ventilated patients (conditional recommendation). However, 97 our data have implications for patient management, and suggest that a subset of patients may likely 98 benefit from antiviral therapy and possibly extended immunomodulatory therapy. Further clinical 99 studies are warranted.

# Introduction.

Coronavirus disease-19 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been the foremost killer globally over the last 3 years. Case fatality risk in hospitalised patients, and particularly in mechanically ventilated patients, during the Beta and Delta waves was particularly high (~50%-70%;¹). Even with the Omicron-related variants, case fatality risk remains significant in the elderly and immunocompromised persons, and in several countries including the UK, Italy, France, Brazil, and prominently in China where there is now an unfolding epidemic of severe COVID-19 disease²-10. Better therapeutic interventions are needed. However, despite considerable research, the pathogenesis of severe COVID-19, relative to viral kinetics, remains incompletely understood.

SARS-CoV-2 detection (ascertained through PCR positivity or antigen detection) can persist for several weeks from symptom onset<sup>11</sup>. Post-mortem studies have shown persistence of SARS-CoV-2 in tissues detected by PCR and immunohistochemistry for up to several weeks after symptom onset<sup>12,13</sup>. However, detection of SARS-CoV-2 in these studies may not represent replication competent virus (detectable only by viral culture) but residual genomic or antigenic material in the tissues. Shedding of replicating virus confirmed through serial viral culture (i.e., *in vitro* replication in human cell lines) from the upper respiratory tract (URT) has been shown to persist for only ~2 to 8 days after symptom onset<sup>11,14-23</sup>. These findings have been confirmed in human lung challenge studies with viable pathogen where virus was cultured from the URT until a median of 4 days (and a maximum of 10 days) from symptom onset<sup>24</sup>. However, hardly anything is known about the compartment-specific duration of actively replicating virus in the lower respiratory tract (LRT), particularly in acute severely ill hospitalised patients undergoing mechanical ventilation. We hypothesised that there is compartment-specific uncoupling of viral replication in severe COVID-19 i.e. replicating virus can persist in the LRT beyond 10 days from symptoms onset, independent of its persistence in the URT, and this persistence may be associated with an altered pulmonary immunity.

Methods.

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

Patients. The decedents (n=42) were recruited from Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa (n=18; Beta group) and Groote Schuur Hospital, Cape Town, South Africa (n=24; Delta group). Ethical approval was obtained from the Human Research Ethics Committee (HREC) of the University of Cape Town (HREC approval number 866/2020) and University of Witwatersrand (HREC approval number M200313). Biosafety approvals were obtained from the Faculty Biosafety Committee of the University of Cape Town (IBC008-2021). Viral culture. To establish the *in vitro* viral culture model, a SARS-CoV-2 viral stock was used to infect the human lung carcinoma cell line, H1299 ACE2, in a BSL3 laboratory and infection was confirmed by light microscopy (as assessed by cytopathic effects of the virus on the cell line) and confocal microscopy (Figure S1A and B). Serial dilutions of the viral stock were used to establish the limit of detection of the PCR assay at  $1\times10^1$  copies/ml (Figure S1C). Viral culture was performed on the nasopharyngeal swab and lung biopsy samples as indicated in the study overview (Figure 1) and detailed in the online supplement. Viral culture was highly reproducible (see online supplement). Multiplex PCR to detect secondary bacterial infections. The lung biopsy cores, stored in universal transport medium, were briefly homogenised and 200µl of the supernatant was applied to the BioFireO FilmArrayO Pneumonia panel (Bioméieux, South Africa). The panel was run using protocol BAL v3.3 according to the manufacturer's instructions, thus generating RT-PCR readouts for 33 bacterial and viral pathogens. Bronchopneumonia was defined as histological evidence of a neutrophilic alveolar infiltration together with the detection of bacterial genomic material in the biopsy cores.

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

Immunohistochemistry. Immunohistochemical staining was performed using the Roche Ventana Automated platform (Ventana XT autostainer) as indicated by the manufacturer. Tissue sections were prepared, stained, and viewed using standard techniques<sup>25</sup>. Antibodies included anti-CD3 (2GV6), anti-CD4 (SP35), anti-CD8 (SP57) and anti-CD68 (KP-1) (Roche USA). Haematoxylin & eosin (H&E) staining and transmission electron microscopy (TEM). H&E staining and TEM were performed according to standard procedures<sup>25</sup>. H&E-stained slides were viewed using an Olympus BX43 microscope. TEM tissue sections were viewed using a Carl Zeiss EM109 microscope. SARS-CoV-2 whole genome sequencing. Total SARS-CoV-2 RNA was extracted from lung biopsy samples and whole genome sequencing was performed. The generated reads were analysed with the Exatype (https://exatype.com) software to identify minor and major variants. The assembled consensus sequences were analysed using Nextclade Web (https://clades.nextstrain.org) for further quality control and clade assignment. RNAseq. Total RNA was extracted from lung biopsy samples, sequenced and mapped consecutively to the human and COVID reference genomes using the Spliced Transcripts Alignment to a Reference (STAR) software (version 2.7.7a, <sup>26</sup>). A differential expression (DE) analysis was performed on the generated raw read count file with the edgeR (Version 3.38.4) R package<sup>27</sup>. A gene set enrichment analysis (GSEA) was performed on the DE results ranked by fold change using the gseGO function, from the R clusterProfiler (Version 4.0, <sup>28</sup>) package.

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

Confocal microscopy. The H1299 ACE2 cells were plated and allowed to adhere to coverslips slides overnight at 37°C. The next day the cells were stained with or without anti-SARS-CoV-2 S1 spike protein (ThermoFisher, USA) and the slides were mounted in Mowiol (Calbiochem, USA) containing n-propyl gallate (Sigma-Aldrich, Germany) as an anti-fading agent. Confocal microscopy was performed with a Zeiss Axiovert 200M LSM510 Meta NLO Confocal Microscope. Lung tissue digestion and flow cytometry. Lung biopsy samples were cut into 1 mm by 1 mm pieces and digested using collagenase II according to the manufacturer's instructions (Ambion, USA). Undigested tissue was removed with a cell strainer (Becton Dickinson, USA) and cells were collected by centrifugation. Prior to antibody staining, the cells were stained with the fixable viability dye, Zombie (Biolegend, USA) in PBS. The cells were stained with antibodies against CD3, CD4, CD8, IFN-γ, TNF-α, IL-2 and IL1-β (Biolegend, USA) then acquired using a LSRII Flow Cytometer (Becton Dickinson, USA) and analysed using FloJo software (version 10.1; Treestar, USA). Dead cells were excluded from the scatter plots prior to analysis, and negative gates were set using fluorescence minus one (FMO) controls. Only the single cellular population was analysed. Statistical analysis. The Fisher Exact test was employed for categorical variables and for continuous variables, Mann-Whitney test was used for non-parametrically distributed data (Stata version 17 or GraphPad, Version 9.4.1). A p-value of < 0.05 was considered significant for all statistical analyses. The DE results were sorted/ranked by fold change and a gene set enrichment analysis (GSEA) for Gene Ontology (Biological Process) and KEGG pathways was performed using the gseGO and gseKEGG functions

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

respectively, from the clusterProfiler (Version: 4.4.4;<sup>28</sup>) package in R. Pathways with an FDR <0.05 were considered significant. **Results** Demographics and clinical characteristics of the decedents. The demographics of patients enrolled in the study are shown in Table S1. The median age of the patients was 53 years with 48% being males (20/42) and 52% being females (22/42). 40.5% (17/42) had a secondary bacterial infection and 11% (4/38) had bacterial bronchopneumonia (microbiologically and histopathological confirmed). The median time from onset of symptoms to death, ICU admission to death and high flow oxygen admission to death was 17 (IQR; 9-22), 5 (2-12) and 11 (6-15) days, respectively. Figure 1A outlines an overview of the study plan. Ambulatory controls (n=18) were recruited at diagnosis (baseline; ~5 days from symptom onset), 7 days post diagnosis and 14 days post diagnosis. Minimally invasive tissue samples (MITS) and nasopharyngeal swabs from decedents (n=42) in the Beta and Delta waves (Figure 1B) were taken immediately after death. In addition, heart, liver, kidney, and adipose tissue samples were taken from the Delta variant decedent cohort. SARS-CoV-2 replicating persistence in the human lung of mechanically ventilated decedents. We first ascertained the frequency and duration of replicating virus in lung tissue (which to our knowledge has not been previously undertaken). Culturable virus was present in 38.1% (16/42; Figure 2A) of mechanically ventilated ICU decedents, at a median of 15 days (and up ~4 weeks) from symptom onset to sampling/death (Figure 3A). By contrast, in a prospectively recruited control group of ambulatory patients 5.5% (1/18) and 0% (0/18) had culturable virus, using nasopharyngeal swab

samples, at day 12 (p=0.012) and 19 (p=0.001) after symptom onset, respectively (Figure 2B). Additionally, SARS-CoV-2 could be detected by PCR in multiple organs in lung culture-positive decedents in the Delta cohort (biopsies other than the lung were not performed in the Beta cohort) suggesting widespread multi-organ viral dissemination (Figure 2C). SARS-CoV-2 was also detected in adipose tissue of culture-positive decedents (hitherto undescribed). Clinical characteristics, such as, age and comorbidities were similar in the lung culture-positive versus culture-negative groups (Table S1). We found no association between viral genetic variant and the phenotype of replicating viral persistence (although this might have been a factor of the limited sample size; Table S5).

#### Time to death in the Delta and Beta groups and predictors of lung culture positivity.

Next, we evaluated variant-specific relationships to clinical outcomes. Mechanically ventilated patients who were SARS-CoV-2 lung culture-positive in the Delta, but not the Beta group, had accelerated death (i.e. shorter duration from symptom onset to death; Figure 3C versus 3B; p=0.004), and a higher proportion of lung-specific secondary bacterial infection (Figure 3F versus 3E; p=0.032) compared to culture-negative decedents. The bacterial species identified from the lung biopsies of both the Beta and Delta groups included *Streptococcus, Staphylococcus, Haemophilus, Acinetobacter*, Proteus spp, *Escherichia, Klebsiella, Enterobacter* and *Serratia* (Table S4). Overall, both groups were infected with one or more bacteria that were sensitive or resistant to β-lactams and/or carbapenems. Key clinical and demographic characteristics such as differences in co-morbidities (age, obesity, diabetes, HIV positivity etc) associated as drivers of severe COVID-19 disease and poor prognosis, could not explain these observations, despite the lower population-level vaccination and pre-existing COVID-19 exposure rates in the Beta cohort. Steroid usage was similar in the culture-positive and culture-negative groups (Table S1) and there was no significant (p>0.05) association between steroid use and the presence of secondary bacterial infection in a multivariable analysis.

Next, we interrogated whether nasopharyngeal PCR characteristics (Ct value), either at admission or close to death, could identify the phenotype of lung replicating viral persistence. However, nasopharyngeal Ct neither at admission, nor at the time of death was associated with lung culture positivity (Figure 3G). This suggests that the kinetics of viral replication was different in the upper and the lower respiratory tract.

#### Lung immunity and histology of the culture-negative versus culture-positive groups.

We then ascertained whether the phenotype of replicating viral persistence was associated with attenuated or modulated lung immunity in the Delta decedents (transcriptomic and flow cytometric studies were only carried out in Cape Town, i.e the Delta decedents, due to location-specific availability of assays and limited Beta group biopsy cores that had been used for unrelated studies). Immunohistochemical staining indicated that there was significantly less infiltration of CD3+ T-cells, specifically CD8+ T-cells in the alveoli and interstitium of the SARS-CoV-2 culture-positive compared with the culture-negative individuals in the Delta decedents (Figure 4A and B; immunohistochemical staining was not performed in the Beta cohort due to limited sample availability as outlined above).

The typical histological features of severe COVID-19 (e.g. diffuse alveolar damage and microvascular thrombosis) were similar in the SARS-CoV-2 culture-positive and the culture-negative phenotype suggesting that these events occurred in the early rather than the persistent viral replication phase (Figure 4C and D). Interestingly, we observed that some features of leucocyte hyperactivation (i.e., hemophagocytic syndrome) were more common in the SARS-CoV-2 culture-negative versus the culture-positive group, potentially in keeping with an aberrant immune response characterised by a lack of immune regulation, as outlined above (Figure 4C; p=0.013).

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

The lung-specific transcriptional analysis at individual gene level identified 630 up- and 885 downregulated genes when comparing the culture-positive versus negative-groups. The 630 significantly upregulated genes highlighted pathways that were associated with a proinflammatory response related to cytokine signalling, neutrophil and monocyte chemotaxis/recruitment, and viral entry/defence, all of which are implicated in COVID-19-related hypercytokinaemia <sup>29</sup> (Figure 5, S7 and S8, Table S6 and S7A). The 885 downregulated pathways were mostly associated with body homeostasis (Figure 5A and B). The same comparison after adjustment for multiple testing, identified a total of 11 up- and 5 down-regulated genes in the culture-positive compared to culture-negative individuals at (FDR<0.05; specific genes discussed further in the online supplement). There was also in tandem upregulation of Th1 and Th17 signalling pathways (Table S7B) but to a substantially lesser extent than that of innate cellular and signalling pathways (IL-1, IL-6 and neutrophil-related). These features may be consistent with an aberrant immune response including a lack of activation of regulatory and immune-suppressive pathways. T-cell exhaustion consistent with upregulation of PD-1, CTLA-4 and LAG (Table S7C) known to be associated with severe COVID-19, was not observed. The differential expression (DE) results also revealed a number of SARS-CoV-2 genes were

The differential expression (DE) results also revealed a number of SARS-CoV-2 genes were significantly upregulated (FDR<0.01) in the culture-positive versus the culture-negative group including *nucleocapsid phosphoprotein* (log2 FC=8.4) and *ORF3a* (log2 FC=5.5) while the *surface/spike glycoprotein* encoding gene had a log2 FC of 5.3 and an FDR of 0.067 (Table S6). A visual inspection of the mapped SARS-CoV-2 reads revealed those that mapped to the 5' end of the genes were spliced with a portion mapping to the 5' leader sequence of the genome. This suggests the reads originated from sub-genomic mRNA (sgRNA) rather than genomic RNA which is consistent with the active viral replication observed in the culture-positive group.

Finally, we evaluated whether any of the differentially expressed genes could act as biomarkers discriminating between lung culture-positive and negative-individuals. Logistic regression predictive

modelling revealed that *GREM1* and *FGFBP1* were associated with a sensitivity and specificity above 90% (further details in the online supplement). Although these are lung-specific biomarkers, this preliminary analysis in a limited number of samples suggests that in the future, RT-PCR of tracheal aspirates or blood (if they are concordant with lung findings), could potentially serve as biomarkers to identify and direct appropriate treatment protocols to culture-positive persons but further investigation is needed.

# Discussion.

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

The widely accepted view in severe acute COVID-19 is that resolution of the initial viral replication phase in the first week after symptom onset is followed by an effector or hyperinflammatory phase in the second and third week of illness, characterised by diffuse alveolar damage, thromboinflammation, and endotheliopathy<sup>30</sup>. Indeed, the Infectious Disease Society of America (IDSA) recommends the use of remdesivir for only 5 days in patients with severe illness and not in mechanically ventilated patients<sup>31</sup>. However, our results, based on post-mortem lung biopsies obtained using minimally invasive tissue sampling methods (MITS; shortly after death) indicated that, in contradistinction to the URT where replication often ceases within ~8 days from symptom onset, in the human lung virus is culturable in ~40% of mechanically ventilated patients until death (median of 15 days and up to 4 weeks after symptom onset; see Figure 1 for the study overview). The culturepositive group in the Delta cohort had accelerated death and a higher proportion of secondary bacterial infection in the lung compared to the culture-negative group. Nasopharyngeal SARS-CoV-2 viral load (based on Ct value) neither at admission nor at death, was predictive of lung culturepositivity. SARS-CoV-2 culture-positivity in the lung of decedents was associated with attenuated pulmonary T-cell immunity and an exaggerated pro-inflammatory phenotype. Importantly, this was concurrent with, rather than sequential to the viral replication or viral culture-positive phase. These findings challenge the traditional paradigm of an initial viral replicative phase in the first week of severe illness sequentially followed by an effector or inflammatory phase<sup>30</sup>. Our data suggest that

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

in ~40% of ventilated patients, viral replication persisted until death (i.e. 3<sup>rd</sup> and 4<sup>th</sup> week of illness and a median of 15 days after symptom onset) compared to ~2 to ~8 days in the URT as outlined in several studies including a live virus human challenge study<sup>11,14-24</sup>. One outlier study reported culturing virus from the URT for up to 3 weeks after symptom onset<sup>32</sup>. However, a large proportion of patients were immunocompromised, samples at diagnosis and follow-up were combined (skewing the results), a high proportion of participants were healthcare workers (re-infection may have been a confounder), and as the authors suggested a limitation was that the Vero cell line used was overtly permissive to infection compared to the human lung carcinoma cell line, H1299 ACE2, which is a biologically representative cell line (and one that we used). Another recent study showed that infectious virus production peaked in the human lung within 2 days, but this model used ex vivo agarose infused devascularised and explanted human lung slices, which are not representative of what is occurring in freshly harvested human lung<sup>33</sup>. The culture-based findings in the afore-mentioned studies must be explicitly distinguished from studies that detected residual free viral genomic RNA (but not replicating virus) embedded in the respiratory tract tissue of patients that had severe disease for an extended period of time<sup>13,34,35</sup>. Indeed, SARS-CoV-2 RNAs have been detected in patient tissue many months after recovery from acute infection 36-38. It was initially suggested that sgRNA (subgenomic RNA; small strands of reversely transcribed RNA) could be used as a proxy to infer viral replication. However, several recent studies have indicated that it has poor predictive value as a proxy for viral replication<sup>39,40</sup>. Indeed, Stein et al<sup>13</sup> detected sgRNA in multiple post-mortem organ biopsies, including the brain, several months after symptom onset. Thus, the data presented in this manuscript is the first to do so conclusively and comprehensively using viral culture from lung tissue (the gold standard to detect viral replication) beyond two weeks after symptom onset.

We demonstrated active viral replication in the lungs of acutely ill ventilated patients for up to ~4 weeks after symptom onset. This challenges the current practice of using antivirals like remdesivir for only 5 days and suggests that a longer duration of treatment may be required in critically ill patients. Furthermore, remdesivir is not recommended for use by IDSA in mechanically ventilated patients

(conditional recommendation) as it felt that such patients (often in the third week of their illness) are no longer in the viral replicative phase, and published controlled trial data showed no mortality benefit of remdesivir in such patients<sup>31,41</sup>. However, these studies demonstrated a group effect, and the analyses did not adjust for disease severity or the time from symptom onset to death in mechanically ventilated patients<sup>42</sup>. Our data suggest that a significant number of patients may likely benefit from antivirals during mechanical ventilation. Indeed, several observational studies have found a survival benefit using remdesivir in mechanically ventilated patients, but this requires further clarification in appropriate trials<sup>42,44</sup>. In a multivariate analysis we found no association between steroid usage and lung viral culture positivity - in fact, steroid usage was lower in the viral culture-positive group and often culture positivity persisted beyond the 10 days of steroid usage.

The transcriptomic data suggested that, in a significant number of patients, the hyperinflammatory and viral replication phase occur concurrently in the 3<sup>rd</sup> and 4<sup>th</sup> week of illness, in contradistinction to the widely held view that these are sequential phases. Antiviral and selective proinflammatory responses were over-represented in the SARS-CoV-2 culture-positive compared with the culture-negative decedents, and we did not detect attenuated type 1 interferon responses at the site of disease compared with other reports<sup>45-49</sup>. Three prior studies (one that enrolled 5 COVID-19 patients) evaluated transcriptomic lung responses in patients with severe COVID-19 versus healthy controls<sup>45,46,50</sup>. These first level studies logically attempted to address the significance of transcriptomic changes specific to COVID-19 by using healthy controls or non-diseased parts of the lung from lung cancer patients. However, we specifically sought to compare culture-positive versus culture-negative groups (hitherto not undertaken) to dissect out pathways that facilitate permissiveness to ongoing viral replication.

There are several limitations to our findings. Firstly, our findings are relevant to acute severe COVID-19 ARDS/pneumonia requiring mechanical ventilation and may not be applicable to milder forms of disease seen in hospitalised patients or chronic infection seen in immunocompromised patients.

Second, we only studied patients with the Beta and Delta variants. However, Omicron has also been associated with severe disease in several settings including the surge of severe COVID-19 unfolding in China. Third, we did not study a control group comprising severe ARDS due to other causes. However, our express aim was to investigate the presence and duration of viral replication in the LRT in severe COVID-19 disease. Fourth, the sample size limited our ability to make conclusions about several aspects. However, the resource intensive and demanding nature of the study limited our ability to recruit higher numbers of participants. Fifth, there may have been sampling error and variability of the viral culture assay. However, the reproducibility of the viral culture technique using 6 samples across 2 separate runs had a low standard error, which was indicative of high reproducibility. Finally, the transcriptional signature and flow cytometric findings may have been affected by post-death sampling, but several detailed studies have shown <sup>51</sup> that most protein and RNA species are preserved and stable for several hours after death. Given that biopsies for the transcriptional studies were taken ~2 hours after death, we feel they are broadly representative of the picture at the time of death.

In summary, our data suggest that in COVID-19 disease there is considerable heterogeneity in the frequency and duration of viral replication in the upper versus the LRT beyond the 2<sup>nd</sup> week of illness, and that in a significant proportion of seriously ill patients, persisting viral replication occurs concurrently and may drive an exaggerated proinflammatory response (higher than in culture-negative persons), rather than sequentially as it is widely believed. These findings have potential implications for the use of antiviral therapy in seriously ill patients with COVID-19 and suggest that better biomarkers are needed to identify patient phenotypes and subsets that might benefit from concurrent anti-inflammatory and antiviral therapy.

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

Figure legends. Figure 1. Study overview including SARS-CoV-2 PCR-positive ambulatory controls (A) and mechanically ventilated decedents (B) recruited during the Beta and Delta waves. Nasopharyngeal (NP) swabs from ambulatory COVID-19 controls were obtained approximately 5 days after symptom onset (diagnosis), and then at 12- and 19-days post symptom onset. Minimally invasive tissue samples (MITS) and NP swabs were retrieved from decedents shortly after death. Figure 2. Active replicating virus was recovered from the lungs of over one third of decedents (16/42). (A) Proportion of lung biopsy samples that were culture-positive. (B) Proportion of serial nasopharyngeal swabs from PCR-positive ambulatory controls compared to lung biopsy samples from culture-positive decedents. (C) PCR positivity of organs of lung culture-positive decedents from the Delta cohort. NP= nasopharyngeal. Figure 3. The phenotype of replicating viral persistence, compared to the culture-negative participants, was associated with accelerated death and a higher frequency of bacterial bronchopneumonia in the Delta but not the Beta group. (A) The days from symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups for both groups combined, and for the Beta (B) and Delta (C) groups alone. Proportion of samples/participants with a secondary bacterial infection in culture-negative and culture-positive decedents overall i.e. the combined groups (Beta and Delta) (D), Beta group only (E), and Delta group only (F). (G) PCR cycle threshold (Ct) value at the time of death or at admission could not discriminate or predict lung culture status. The nasopharyngeal swab PCR Ct values at admission or death were missing for some participants because they were either diagnostically confirmed by antigen testing or the Ct value was not recorded. Due to the nature of the pandemic and the burden of the disease on the healthcare infrastructure at the time, Ct values at peak periods were not recorded. We have conducted sensitivity and imputation analyses indicating that these missing data points are redundant. The nasopharyngeal swab PCR Ct values at admission or death were missing for some participants because they were either diagnostically confirmed by antigen testing or the Ct value was not recorded. Due to the nature of the pandemic and the burden of the disease on the

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

healthcare infrastructure at the time, Ct values at peak periods were not recorded. We have conducted sensitivity and imputation analyses indicating that these missing data points are redundant. Figure 4. A higher proportion of T-cells, macrophages and pneumonocytes infiltrate into the lung of the culture-negative versus culture-positive decedents in the Delta group. (A) More CD3+ and CD8+ T-cells infiltrate into the alveoli and interstitial space of the lung culture-negative versus culture-positive group in the Delta decedents as assessed by immunohistochemistry. (B) Representative images (immunohistochemistry) showing increased T-cell infiltration into interstitial space (blue arrow) in the lung culture-negative versus the culture-positives in the Delta cohort. Histopathology findings (C) and representative images (D) associated with diffuse alveolar damage and microvascular thrombosis in the Delta decedents. The black arrows indicate key histopathological features. Figure 5. The transcriptomic analysis revealed that the culture-positive group, in comparison to the culture-negative group, had enrichment of activated pathways associated with inflammation, innate immunity, responses to cytokines, and responses to virus/ bacterial stimuli in the Delta descendants. Dot plot illustrating the significantly activated and suppressed pathways along with the gene count and ratio for each pathway (A), enrichment map illustrating the significantly activated and suppressed pathways along with the gene count and ratio for each pathway (B) and cnetplot similarly illustrating the overlap of genes and their fold changes for selected activated pathways (C).

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

**Contributions** K.D, MT, S.J, A.P, A.E, M.D, M.N and S.M conceived and designed experiments. K.D, A.E, S.O, L.K, T.P, A.S, I.J, J.P, D.T, D.F, M.M, M.N and S.M arranged medical ethical approval, recruitment of study participants and collection of study material. MT, SJ. A.P, L.W, A.K, S.M, K.P, R.R, R.K, R.M, C.M, J.B, R.L, M.D, C vdM, A.R, M.H, V.B, S. M, C.W, and R.J performed the experiments. M.T, S.J, A.P and M.D set up experimental assays. A.S provided the cell line. K.D, M.T, S.J, A.P, L.W, A.K, L.S, S.M, K.P, R.R, R.L, M.H, V.B, S.M, R.J, and N.M analysed and interpreted data. K.D, M.T, L.S, and S.M wrote the manuscript with input from all listed authors. **Declaration of interests** The authors have no competing interests. Acknowledgments The authors would like to thank Arnold-Day C, Crowther M, Fernandes N, and Mitchell L from the Division of Critical Care, Department of Anaesthesia and Perioperative Medicine, University of Cape Town, South Africa for identifying and referring potential patients into the study. The study was funded by the Bill & Melinda Gates Foundation (grant number INV-017282) and the South African Medical Research Council (grant number SHIP NCD 96756) with partial support from the Department of Science and Technology and National Research Foundation: South African Research Chair Initiative in Vaccine Preventable Diseases. The KD lab acknowledges funding from the SA MRC (RFA-EMU-02-2017), EDCTP (TMA-2015SF-1043, TMA-1051-TESAIII, TMA-CDF2015), UK Medical Research Council (MR/S03563X/1), NIH (CRDF-OISE-16-62105) and the Wellcome Trust (MR/S027777/1). This work was co-funded by The Wellcome Centre for Infectious Diseases Research in Africa is supported by core funding from the Wellcome Trust (230135/Z/16/Z)

- 477 and the European Union's Horizon Europe Research and Innovation Actions (101046041) for
- 478 genomic surveillance.
- 479 The authors would like to thank the families of the deceased who gave us permission to conduct the
- 480 study, which may advance our understanding of SARS-CoV-2 pathogenesis to inform future clinical
- 481 management of respiratory pathogen pandemics.


#### References.


482

- 484 Davies MA, Morden E, Rosseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection
- 485 during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western
- 486 Cape Province, South Africa. Int J Infect Dis 2022; 127: 63-8.
- 487 Johns Hopkins University Center for Systems Science and Engineering. Accessed on: 18 December
- 488 2022. Available at: <a href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</a> 2022.
- 489 Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China. Nat Med 490 2022; 28(7): 1468-75.
- 491 Chen X, Yan X, Sun K, et al. Estimation of disease burden and clinical severity of COVID-19 caused
- 492 by Omicron BA.2 in Shanghai, February-June 2022. Emerg Microbes Infect 2022; 11: 2800-7.
- 493 Colnago M, Benvenuto GA, Casaca W, Negri RG, Fernandes EG, Cuminato JA. Risk factors 494 associated with mortality in hospitalized patients with COVID-19 during the Omicron wave in Brazil. Bioeng
- 495 2022; 9(10).
- 496 Gautret P, Hoang VT, Jimeno MT, et al. The severity of the first 207 infections with the SARS-CoV-2
- 497 Omicron BA.2 variant, in Marseille, France, December 2021-February 2022. J Med Virol 2022; 94(8): 3494-7.
- 498 Jassat W, Mudara C, Ozougwu L, et al. Difference in mortality among individuals admitted to hospital 499 with COVID-19 during the first and second waves in South Africa: a cohort study. Lancet Glob Health 2021;
- 500 **9**(9): e1216-e25.
- 501 Maruotti A, Ciccozzi M, Jona-Lasinio G. COVID-19-induced excess mortality in Italy during the 502 Omicron wave. *IJID Reg* 2022; **4**: 85-7.
- 503 Maslo C MA, Laubscher A, Toubkin M, Sitharam L, Feldman C, Richards GA. COVID-19: A
- 504 comparative study of severity of patients hospitalized during the first and the second wave in South Africa. 505 *MedRXiv* 2021; https://doi.org/10.1101/2021.05.11.21257033.
- 506 Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of covid-19 related deaths for SARS-CoV-2 507 Omicron (B.1.1.529) compared with Delta (B.1.617.2): retrospective cohort study. BMJ 2022; 378: e070695.
- 508 Fontana LM, Villamagna AH, Sikka MK, McGregor JC. Understanding viral shedding of severe acute
- 509 respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. Infect Control Hosp Epidemiol
- 510 2021; **42**(6): 659-68.
- 511 Ramos-Rincon JM, Herrera-Garcia C, Silva-Ortega S, et al. Pathological findings associated with
- 512 SARS-CoV-2 on postmortem core biopsies: correlation with clinical presentation and disease course. Front Med 513 2022; 9: 874307.
- 514 13.
- Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and 515 brain at autopsy. Nature 2022; 612(7941): 758-63.
- 516 Basile K, McPhie K, Carter I, et al. Cell-based culture informs infectivity and safe de-isolation 517 assessments in patients with coronavirus disease 2019. Clin Infect Dis 2021; 73(9): e2952-e9.
- 518 Berengua C, Lopez M, Esteban M, et al. Viral culture and immunofluorescence for the detection of 15.
- 519 SARS-CoV-2 infectivity in RT-PCR positive respiratory samples. J Clin Virol 2022; 152: 105167.
- 520 16. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 521 from diagnostic samples. Clin Infect Dis 2020; 71(10): 2663-6.
- 522 17. Lan L, Xu D, Ye G, et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA 523 2020; **323**(15): 1502-3.
- 524 18. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus 525 disease rehabilitation patients. Chin Med J 2020; **133**(9): 1039-43.


- 526 19. Santos Bravo M, Berengua C, Marin P, et al. Viral culture confirmed SARS-CoV-2 subgenomic RNA
- 527 value as a good surrogate marker of infectivity. J Clin Microbiol 2022; **60**(1): e0160921.
- 528 Singanavagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR
- 529 cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill 2020; 25(32).
- 530 van Kampen JJA, van de Vijver D, Fraaij PLA, et al. Duration and key determinants of infectious virus 21.
- 531 shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun 2021; 12(1): 267.
- 532 Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with 533 COVID-2019. Nature 2020; **581**(7809): 465-9.
- 534 Young BE, Ong SWX, Ng LFP, et al. Viral dynamics and immune correlates of coronavirus disease
- 535 2019 (COVID-19) severity. Clin Infect Dis 2021; **73**(9): e2932-e42.
- 536 Killingley B, Mann AJ, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-CoV-2
- 537 human challenge in young adults. Nat Med 2022; 28(5): 1031-41.
- 538 Suvarna SK, Layton C, Bancroft JD. Banfords theory and practice of histology techniques. Elsevier 25. 539 2019.
- 540 26. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinform 2013; 541 **29**(1): 15-21.
- 542 Howe KL, Achuthan P, Allen J, et al. Ensembl 2021. Nucleic Acids Res 2021; 49(D1): D884-D91.
- 543 Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. 544 Innov 2021; 2(3): 100141.
- 545 Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we 546 know so far. Fron Immunol 2020; 11: 1446.
- 547 Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. 548 Science 2022; 375(6585): 1122-7.
- 549 Bhimraj A MR, Shumaker AH, Baden L, Cheng VC, Edwards KM, Gallagher JC, Gandhi RT, Muller
- 550 WJ, Nakamura MM, O'Horo JC, Shafer RW, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytte Y.
- 551 IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Accessed on: 18 December
- 552 https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-2022. Available at:
- 553 management/#Recommendations15-17:Remdesivir.
- 554 Folgueira MD, Luczkowiak J, Lasala F, Perez-Rivilla A, Delgado R. Prolonged SARS-CoV-2 cell 32.
- 555 culture replication in respiratory samples from patients with severe COVID-19. Clin Microbiol Infect 2021; 556 **27**(6): 886-91.
- 557 Pechous RD, Malaviarachchi PA, Banerjee SK, et al. An ex vivo human precision-cut lung slice
- 558 platform provides insight into SARS2 CoV-2 pathogenesis and antiviral drug efficacy. bioRxiv 2023; 559 doi:10.1101/2023.04.18.537373.
- 560 Xu Q, Milanez-Almeida P, Martins AJ, et al. Adaptive immune responses to SARS-CoV-2 persist in 561 the pharyngeal lymphoid tissue of children. *Nat Immunol* 2023; **24**(1): 186-99.
- 562 Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen 563 Persistence in Inflammatory Bowel Diseases. Gastroenterol 2022; 163(2): 495-506 e8.
- 564 Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an 565 Immunocompromised Host. NEJM 2020; **383**(23): 2291-3.
- 566 Griffin I, Woodworth KR, Galang RR, et al. Recurrent SARS-CoV-2 RNA Detection after COVID-19 567 Illness Onset during Pregnancy. Emerg Infect Dis 2022; 28(4): 873-6.
- 568 Rodriguez-Grande C, Alcala L, Estevez A, et al. Systematic genomic and clinical analysis of severe 569 acute respiratory syndrome coronavirus 2 reinfections and recurrences involving the same strain. Emerg Infect 570 Dis 2022; 28(1): 85-94.
- 571 Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic 572 samples are not an indicator of active replication. *Nat Commun* 2020; **11**(1): 6059.
- 573 Hwang HS, Lo CM, Murphy M, et al. Characterizing SARS-CoV-2 Transcription of Subgenomic and
- 574 Genomic RNAs During Early Human Infection Using Multiplexed Droplet Digital Polymerase Chain Reaction.
- 575 J Infect Dis 2023; **227**(8): 981-92.
- 576 Consortium WHOST. Remdesivir and three other drugs for hospitalised patients with COVID-19: final
- 577 results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 2022; 399(10339): 1941-53.
- 578 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. 579 NEJM 2020; **383**(19): 1813-26.
- 580 Lapadula G, Bernasconi DP, Bellani G, et al. Remdesivir Use in Patients Requiring Mechanical 581
- Ventilation due to COVID-19. Open Forum Infect Dis 2020; 7(11): ofaa481. 582 44. Pasquini Z, Montalti R, Temperoni C, et al. Effectiveness of remdesivir in patients with COVID-19
- 583 under mechanical ventilation in an Italian ICU. J Antimicrob Chemother 2020; 75(11): 3359-65.
- 584 Budhraja A, Basu A, Gheware A, et al. Molecular signature of postmortem lung tissue from COVID-19
- 585 patients suggests distinct trajectories driving mortality. Dis Model Mech 2022; 15(5).

- 586 46. Melms JC, Biermann J, Huang H, et al. A molecular single-cell lung atlas of lethal COVID-19. *Nature* 587 2021; **595**(7865): 114-9.
- 588 47. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* 2020; **20**(6): 363-74.
- 590 48. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for
- COVID-19. Nat Med 2022; 28(1): 39-50.
  Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature
- 592 49. Wang EY, Mao 1, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. *Nature* 593 2021; **595**(7866): 283-8.
- 594 50. Wang S, Yao X, Ma S, et al. A single-cell transcriptomic landscape of the lungs of patients with 595 COVID-19. *Nat Cell Biol* 2021; **23**(12): 1314-28.
- 596 51. Deinhardt-Emmer S, Wittschieber D, Sanft J, et al. Early postmortem mapping of SARS-CoV-2 RNA 597 in patients with COVID-19 and the correlation with tissue damage. *Elife* 2021; **10**.






<sup>\*</sup>The 16 decedents that were nasopharyngeal culture-positive were not the same patients that were lung culture-positive. #Immunohistochemistry, RNAseq, electron microscopy and viral culture of other organs was only performed on the Delta cohort.



Culture-positivity was defined as at least a 3-fold exponential increase in viral load over time.



A

A greater proportion of CD3+ T-cells and CD8+ T-cells infiltrate into the alveoli and interstitial space in culturenegative compared to culture-positive individuals in the Delta decedents

	Lung culture status			
Frequency of	-ve (n=11#)	+ve (n=7*)	p value	
infiltration into the				
alveoli				
CD3+				
Medium	55%(6/11)	0% (0/7)	0.038	
High	0% (0/11)	0% (0/7)	N/A	
CD8+				
Medium	54.5% (6/11)	0% (0/7)	0.038	
High	0% (0/11)	0% (0/6)	N/A	

CD68 (macrophage marker)

A greater proportion of type II pneumonocytes proliferation and haemophagocytosis was observed in the alveoli of the culture-negative compared to culture-positive individuals in the Delta group


	Lung culture status			
Lung histology	-ve (n=20◆)	+ve (n=13*)	p-value	
Alveolar hyaline	16/20 (80%)	8/13 (61.5%)	0.425	
medRxiv preprint doi: https://doi.org/10.1101/2023.03.06.23286834; this version posted June 1, 2023. The copyri	ght holder for this preprint			
medRxiv preprint doi: https://doi.org/10.1101/2023.03.06.23286834; this version posted June 1, 2023. The copyri (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display to the lit is made a allable under a CC-BY-ND 4.0 International license.	he preprint in perpetuity. 6/20 (30%)	5/13 (38.5%)	0.714	
thrombosis				
Organising hyaline	9/12 (75%)	6/7 (86%)	1	
membranes				
Type II pneumocytes	20/20 (100%)	10/13 (77%)	0.052	
proliferation				
Organising pneumonia	6/20 (30%)	4/13 (31%)	1	
Lung	14/20 (70%)	3/13 (23%)	0.013	
haemophagocytosis				

B

Representative images showing CD3+ and CD8+ T-cells infiltration into the alveoli and interstitial space of the lung in culture-negative compared to culturepositive individuals in the Delta decedents

# Lung culture-negative


CD3+ T-cells




Lung culture-positive

CD3+ T-cells

CD8+ T-cells






Both culture-positive and culture-negative decedents present with histopathological findings typically associated with SARS-CoV-2 pneumonia


Organising hyaline membranes


D


Alveolar hyaline membranes

Organising pneumonia









Proliferating type 2 pneumocytes

Lung haemophagocytosis

Pulmonary vascular endotheliopathy

